« Return to News | R&D Trends

Johnson & Johnson opens London Innovation Center

Friday, June 7, 2013 01:49 PM

Johnson & Johnson has opened the J&J Innovation Center in London, one of four regional hubs being established this year.  The goal of the Innovation Center is to accelerate early stage science and advance the development of new healthcare solutions.

"The London Innovation Center is part of Johnson & Johnson's broader innovation strategy to advance human health through collaboration with the world's leading scientists and entrepreneurs,” said Paul Stoffels, M.D., J&J chief scientific officer and worldwide chairman, pharmaceuticals.

The Innovation Center will house science and technology experts with expertise in developing new solutions and products.  The Center will have local deal-making capabilities to flexibly adapt deal structures to match early-stage opportunities. This will enable scientists, entrepreneurs and emerging companies to deliver innovation via collaboration with experts who can drive partnerships across the pharmaceutical, medical device & diagnostics and consumer healthcare companies of J&J.

Similar facilities are planned in Boston, San Francisco and Shanghai.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.